Inocras Secures $31M to Bring Asia-Proven Genome Tech to U.S. Oncology

SAN DIEGO, CA – August 03, 2026 – Bioinformatics company Inocras Inc. has successfully closed an oversubscribed $31 million Series B-3 financing round, signaling a major strategic push into the competitive U.S. healthcare market. The new capital brings the company's total funding to approximately $100 million and is earmarked to accelerate the American commercial expansion of its whole-genome sequencing (WGS) and proprietary analytics platform.

Having already established a significant clinical footprint across Asia, Inocras is now poised to challenge established players in the U.S. precision oncology space. The move represents a classic strategic shift: leveraging proven success and a robust technological platform in one region to fuel ambitious growth in another, larger market. The financing, which saw participation from new and existing investors, including strategic partners NDS Corporation and Aimed Bio Inc., underscores a growing confidence in the power of comprehensive genomic data to redefine cancer care.

“We have already seen meaningful adoption across cancer institutions in Asia, where our technology has been used in thousands of patient cases,” said Jehee Suh, CEO of Inocras. “Our next objective is to bring that clinical experience to the United States and help make whole-genome analysis a standard part of cancer care.”

A New Challenger in a Crowded Field

Inocras enters a U.S. precision oncology market valued at nearly $40 billion, a landscape dominated by formidable incumbents like Foundation Medicine and Caris Life Sciences. These companies have pioneered the use of next-generation sequencing (NGS) with widely adopted panel-based tests that analyze hundreds of specific cancer-related genes. However, Inocras is betting on a more comprehensive approach: whole-genome sequencing.

Unlike targeted panels or even whole-exome sequencing, which covers only 1-2% of a person's DNA, WGS analyzes the entire genetic code. This allows for the detection of a broader array of genomic alterations, including complex structural variations and changes in non-coding regions that are often missed by narrower tests. This comprehensive view is the cornerstone of Inocras's value proposition, promising deeper insights for treatment selection, clinical trial matching, and understanding a patient's unique cancer biology.

Despite the technological promise, the path to market adoption is fraught with challenges. The most significant barrier, according to industry analysts, remains reimbursement. Navigating the complex web of payer policies and prior authorization requirements for advanced genomic tests can be a significant hurdle. Furthermore, widespread clinical adoption depends on demonstrating clear clinical utility and educating oncologists, many of whom report difficulty interpreting the vast amount of data generated by genomic tests. Inocras aims to overcome this by pairing its powerful sequencing with a sophisticated bioinformatics engine designed to deliver clear, actionable reports.

Beyond the Sequence: The Power of Bioinformatics

At the heart of Inocras's strategy is its proprietary bioinformatics and automated interpretation platform. The company emphasizes that its value lies not just in sequencing the genome, but in translating that massive, complex dataset into clinically relevant insights. This is embodied in its flagship oncology solutions, CancerVision™ and MRDVision™.

CancerVision™ is a comprehensive tumor-profiling test that provides a “2 in 1” analysis of both tumor (somatic) and inherited (germline) DNA from a single test. This integrated approach provides a holistic picture of a patient's cancer, identifying actionable biomarkers that can guide personalized therapy. In a head-to-head comparison, CancerVision demonstrated 100% concordance with Illumina’s widely used TSO500 panel test while also identifying additional clinically relevant deletions that the panel missed.

The company’s technological prowess was further validated through a high-profile collaboration with the Broad Institute of MIT and Harvard. Together, they reanalyzed over 8,000 whole cancer genomes from The Cancer Genome Atlas, creating a massive, harmonized dataset that demonstrates the utility of standardized WGS at scale and helps reveal genomic drivers located outside of well-trodden coding regions.

Building on this foundation, Inocras recently launched MRDVision™ for detecting molecular residual disease—the trace amounts of cancer cells that can remain after treatment and lead to relapse. Unlike competing MRD tests that create a small, patient-specific panel of mutations to track, MRDVision utilizes a tumor-informed, panel-free WGS approach. This method continuously scans the entire genome for tumor signals, offering ultra-high sensitivity capable of detecting cancer DNA at a rate as low as one part per million. This enhanced sensitivity could prove critical for more accurately monitoring treatment response and making earlier decisions about patient care.

From Asian Success to American Ambition

Inocras’s U.S. expansion is not a speculative venture but a calculated next step built on a proven track record. The company's solutions are already in use at over 100 cancer institutions across Asia, particularly in South Korea and Hong Kong, where they have been applied in thousands of patient cases. This real-world clinical deployment provides a powerful foundation of evidence and operational experience as it establishes its commercial and laboratory infrastructure in the U.S. from its base in San Diego.

The oversubscribed funding round reflects strong investor belief in this growth model. The participation of strategic investors like Aimed Bio, which will use Inocras's platform to support its antibody-drug conjugate (ADC) clinical trials, highlights the technology's applicability beyond diagnostics into therapeutic development. By helping to identify biomarkers and select patients for trials, the platform becomes an integral part of the broader oncology ecosystem.

To support this expansion and manage the immense data processing requirements, Inocras has strategically migrated its platforms to cloud infrastructure, reportedly achieving a 72% reduction in analysis costs and a 47% improvement in processing speed. This commitment to scalability and efficiency is crucial for realizing the company's goal. As Jehee Suh stated, “This financing gives us the resources to expand our clinical presence, support adoption within hospitals, and build the evidence and infrastructure required to achieve that goal.”